Boston Scientific, Bard Reach Distribution Agreement for Drug-Coated Balloon
Boston Scientific will market C. R. Bard’s Lutonix 035 drug-coated balloon percutaneous transluminal angioplasty catheter in the U.S. under a limited distribution agreement, the companies said Monday.
Lutonix DCB is used to deliver the microtubule inhibitor paclitaxel in patients with peripheral artery disease. The device was the first drug-coated balloon PTCA approved by the FDA, the Murray Hill, N.J.-based Bard said.
Jeff Mirviss, head of peripheral interventions at Boston Scientific, the Lutonix DCB will complement the devicemakers’ portfolio of vascular products.
Steve Williamson, president of Bard’s peripheral vascular unit, said the agreement will further expand access to Lutonix DCB. Terms were not disclosed. — Kellen Owings